Matrix metalloproteinase inhibitors

Details Matrix metalloproteinase inhibitors Matrix metalloproteinase inhibitors

2006-06-13

2006-06-13

Jones, Dameron (Department: 1618)

Drug, bio-affecting and body treating compositions

In vivo diagnosis or in vivo testing

C424S001110, C424S001650

Reexamination Certificate

active

07060248

ABSTRACT:
Thus the present invention describes diagnostic agents comprising a diagnostic metal and a compound, wherein the compound comprises: 1-10 targeting moieties; a chelator; and 0-1 linking groups between the targeting moiety and chelator; wherein the targeting moiety is a matrix metalloproteinase inhibitor; and wherein the chelator is capable of conjugating to the diagnostic metal. The present invention also provides novel compositions of the compounds of the invention, kits, and their uses in diagnosis of diseases associated with MMPs.

REFERENCES:
patent: 4859777 (1989-08-01), Toner
patent: 4988827 (1991-01-01), Bergstein et al.
patent: 5064956 (1991-11-01), Kruper, Jr.
patent: 5087440 (1992-02-01), Cacheris et al.
patent: 5155215 (1992-10-01), Ranney
patent: 5281704 (1994-01-01), Love et al.
patent: 5412148 (1995-05-01), Keana
patent: 5417959 (1995-05-01), Wallace
patent: 5520904 (1996-05-01), Nosco et al.
patent: 5567411 (1996-10-01), Keana et al.
patent: 5674754 (1997-10-01), Ahrens et al.
patent: 5679810 (1997-10-01), Love et al.
patent: 5739789 (1998-04-01), Kronhamn
patent: 5750088 (1998-05-01), Sworin et al.
patent: 5760191 (1998-06-01), Snow et al.
patent: 5801228 (1998-09-01), Hollister et al.
patent: 5804161 (1998-09-01), Long et al.
patent: 5879659 (1999-03-01), Edwards et al.
patent: 6057336 (2000-05-01), Duan et al.
patent: 6172057 (2001-01-01), Venkatesan et al.
patent: 6254852 (2001-07-01), Glajch et al.
patent: 6268379 (2001-07-01), Xue et al.
patent: 6365587 (2002-04-01), Voss et al.
patent: 6429213 (2002-08-01), Xue et al.
patent: 6455522 (2002-09-01), Duan et al.
patent: 6495548 (2002-12-01), Duan
patent: 6576664 (2003-06-01), Yao et al.
patent: 6656448 (2003-12-01), Carpenter, Jr. et al.
patent: 0 107 734 (1984-05-01), None
patent: 0 727 225 (1996-08-01), None
patent: WO 91/14460 (1991-10-01), None
patent: WO 92/17215 (1992-10-01), None
patent: WO 94/22496 (1994-10-01), None
patent: WO 97/36619 (1997-10-01), None
patent: WO 98/47541 (1998-10-01), None
patent: WO 99/40947 (1999-08-01), None
patent: WO 99/64406 (1999-12-01), None
Anthony, et al.,Gastroenterology, 1992, Abstract 591.
Armstrong, P.W., et al.,Can. J. Cardiol., 1994, 10, 214-220.
Beckett, et al.,Research Focus, 1996, 1, 16-26.
Beckett, et al.,Curr. Opin. Ther. Patents, 1994, 4(1), 7-16.
Bond, B.R., et al.,Circulation, 1999, 100(Suppl. ), 1-12.
Brown, et al.,Circulation, 1995, 91, 2125-2131.
Coker, et al.,Am. J. Physiol., 1998, 274, H1516-H1523.
Davidsen, et al.,Exp. Opin. Ther. Patents, 1995, 5(2), 1087-1100.
Davies, M.J.,Circulation, 1996, 94, 2013-2020.
Dollery, et al.,Circ. Res., 1995, 77, 863-868.
Falk, et al.,Circulation, 1994, 90, 775-778
Falk, et al.,Circulation,1995, 92, 657-671.
Galis, et al.,J. Clim. Invest., 1994, 94, 2493-2503.
Garbisa, et al.,Cancer Res., 1992, 52, 4548.
Henney, et al.,Proc. Natl. Sci., 1991, 88, 8154-8158.
Libby, P.,Circulation, 1995, 91, 2844-2850.
Lu, et al.,Circulation, 1999, 100 (Suppl. 1), 1-12.
Matthes, et al.,Gastroenterology, 1992, Abstract 661.
Murphy, et al.,Curr. Medicinal Chem., 1995, 2, 743-762.
Porter, et al.,Exp. Opinion Ther. Patents, 1995, 5(12), 1287-1196.
Rohde, et al.,JACC, 1999, 33, 835-842.
Walakovits, et al.,Arth. Rheum., 1992, 35, 35.
Whittaker, et al.,Chem. Rev., 1999, 99, 2735-2776.
Zucker, et al.,Cancer Res., 1993, 53, 140.
Andrews D.R., et al., “Reaction of aziridinium iions with organometallic reagents: optimization of the key step step of ecopipam synthesis,”Tetrahedron Letts., 2002, 43, 6121-6124.
Antunes, M.L., et al., “Diagnosis of right ventricular acute myocardial infarction by dual isotope thallium-201 and indium-111 antimyosin SPECT imaging,”Am. J. Cardiol., August 15, 1992, 70, 426-431.
Babine, R.E., et al., “Molecular recognition of protein—ligand complexes: applications to drug design,”Chem. Rev., 1997, 97, 1359-1472.
Beckett, R.P., et al., “Recent advances in matrix metalliproteinase inhibitor research,”Drug Discovery Today, Jan. 1996, 1(1), 16-26.
Bousquet, J.—C., “Gd-DOTA: characterization of a new paramagnetic complex,”Radiology, 1988, 166, 693-698.
Brechbiel, M.W., et al., “Synthesis of C-functionalizedtrans-cyclohexyldiethylenetriaminepenta-acetic acids for labeling of monoclonal antibodies with the bismuth-212 α-particle emitter,”J.Chem. Soc. Perkin Trans., 1992, 1, 1173-1178.
Brechbiel, M.W., et al., “Backbone-substituted DTPA ligands for90Y radioimmunotherapy,”Bioconjugate Chem., 1991, 2(3), 187-194.
Brinkley, M., “A brief survey of methods for preparing protein conjugates with dyes haptens, and cross-linking reagents,”Bioconjugate Chem., 1992, 3, 2-13.
Cheung, S.T., et al., “N-methylamino acids in peptide sunthesis. VI. A method for determining the enantiomeric purity of N-methylamino acids and their derivatives by ion-exchange chromatography as their C-terminal lysyl dipeptied,”Can. J. Chem., 1977, 55, 911-915.
Davidsen, S.K., et al., “Pulmonary-allergy, dermatological, gastrointestinal & arthritis; inhibitors of TNFα synthesis”Exp. Opin. Ther. Patents, 1995, 5(10), 1087-1110.
De, B., et al., “The next generation of MMP inhibitors,”Ann. N.Y. Acad. Sci., 1999, 878, 40-60.
DeGrado, W.F., et al., “Polymer-bound oxime esters as supports for solid-phase peptide synthesis. Preparation of protected peptide fragments,”Am. Chem. Soc., 1980, 45, 1295-1300.
Deshpande, S.V., et al., “Yttrium-90-labeled monoclonal antibody for therapy: labeling by a new macrocyclic bifunctional chelating agent,”J. Nucl. Med., 1990, 31, 473-479.
Hubbuch, A., et al., “Synthesis of N-protected cysteic acid derivatives and their activated esters,”Liebigs Ann. Chem., 1979, 776-783 (English Abstract included).
Johnson, W.H., et al., “Collagenase inhibitors: their design and potential therapeutic use,” J. Enz. Inhib., 1987, 2, 1-22.
Levin, J.I., et al., “The asymmetric synthesis andin vitrocharacterization of succinyl mercaptoalcohol and mercaptoketone inhibitors of matrix metalloproteinases,”Bioorg. & Med. Chem. Lett., 1998, 8, 1163-1168.
Lovejoy, B., et al., “Crystal structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors,”Nature Struct. Biol., Mar. 1999, 6(3), 217-221.
MacPherson, L.J., et al., “Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage in rabbits,”J. Med.Chem., 1997, 40, 2525-2532.
Margerstadt, M., et al., “Gd(DOTA): an alternative to Gd(DTPA) as a T1,2relaxation agent for NMR imaging or spectroscopy,”Magn. Reson. in Med., 1986, 3, 808-812.
Merrifield, R.B., “Solid phase peptide sysnthesis. I. The synthesis of a tetrapeptide,”J. Am. Chem. Soc., 1963, 85, 2149-2154.
Miller, A., et al., “Inhibition of matrix metalloproteinases: an examination of the S1'pocket,”Bioorg.&Med. Chem. Lett., 1997, 7(2), 193-198.
Morphy, J.R., et al., “Matrix metalloproteinase inhibitors: current status,”Curr. Medicinal Chem., 1995, 2, 743-762.
Porter, J.R., “Oncologic, Ondocrine & Metabolic; recent developments in matrix metalloproteinase inhibitors,”Exp. Opin. Ther. Patents, 1995, 5(12), 1287-1296.
Roberts, D.C., et al., “Unsual amino acids in peptide synthesis,”The Peptides, Academic Press, New York, 1983, vol. 5, Chapter 6, 342-449.
Remington's Pharmaceutical Science, 17thEd., 1985,Mack Publishing Co., Easton, PA, p. 1418.
Runge, V.M., et al., “MR imaging of rat brain glioma: Gd-DTPA versus Gd-DOTA1,”Radiology, 1988, 166, 835-838.
Sahoo, S.P., et al., “Inhibition of martrix metalloptoyrinses by N-carboxyalkyl dipeptides: enhanced potency and selectivity with substituded P1' homophenylalanines,”Bioorg.&Med. Chem. Lett., 1995, 5(20), 2441-2446.
Santos, O., et al., “Rodent pharomacokinetic and anti-tumor effiacy studies with a series of synthethic inh

Affiliated with

Also associated with

Rating

Matrix metalloproteinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Matrix metalloproteinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Matrix metalloproteinase inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3675264